
Personalis PSNL
€ 5.48
-4.92%
Quartalsbericht 2026-Q1
hinzugefügt 07.05.2026
Personalis Betriebsaufwand 2011-2026 | PSNL
Betriebsaufwand Jährlich Personalis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 44.5 M | 25.6 M | 19.8 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 44.5 M | 19.8 M | 30 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 1.31 | -19.63 % | $ 1.74 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 112.11 | -1.0 % | $ 34.1 B | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 19.11 | 1.19 % | $ 554 M | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 15.85 | -2.1 % | $ 479 M | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
3.69 B | $ 142.72 | -0.36 % | $ 22.7 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 19.85 | -3.12 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 93.78 | -2.99 % | $ 6.33 B | ||
|
Medpace Holdings
MEDP
|
118 M | $ 418.32 | -0.2 % | $ 12.1 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 038.75 | -0.3 % | $ 21.4 B | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
964 M | $ 3.62 | - | $ 335 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
430 M | $ 8.29 | -0.9 % | $ 1.06 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 152.19 | -4.36 % | $ 7.54 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
National Research Corporation
NRC
|
38.5 M | $ 18.61 | -1.69 % | $ 417 M | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
258 M | $ 188.15 | -4.45 % | $ 18.5 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 25.27 | -0.96 % | $ 24 B | ||
|
Guardant Health
GH
|
226 M | $ 94.27 | -4.45 % | $ 11.8 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 116.56 | -0.45 % | $ 9.61 B | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 5.72 | -1.72 % | $ 239 M | ||
|
Soleno Therapeutics
SLNO
|
181 M | $ 53.0 | 0.01 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.25 | -6.67 % | $ 5.17 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 252.68 | -0.53 % | $ 21 B | ||
|
Thermo Fisher Scientific
TMO
|
7.15 B | $ 438.85 | -2.07 % | $ 165 B | ||
|
Trinity Biotech plc
TRIB
|
28.3 M | $ 0.56 | -3.63 % | $ 201 M | ||
|
Celcuity
CELC
|
172 M | $ 135.17 | 0.33 % | $ 6.32 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
116 M | $ 48.65 | -8.12 % | $ 2.91 B | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 8.21 | -2.61 % | $ 1.78 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 187.55 | -0.21 % | $ 20.8 B | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M |